DESCRIPTION
id: 65baf8c0-f035-5050-e053-2a91aa0aa788
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3
Alprazolam is a triazolo analog of the 1,4 benzodiazepine class of central nervous system-active compounds. The chemical name of alprazolam is 8-Chloro-1-methyl-6-phenyl-4
H–
s-triazolo [4,3-α] [1,4] benzodiazepine. The structural formula is:
Alprazolam is a white to off-white crystalline powder, which is soluble in alcohol but which has no appreciable solubility in water at physiological pH.
Each alprazolam tablet, for oral administration, contains 0.25, 0.5, 1 or 2 mg of alprazolam.
Alprazolam tablets, 2 mg, are multi-scored and may be divided as shown below:
Inactive ingredients: docusate sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch, and sodium benzoate. Additionally, the
0.5 mg also contains FD & C Yellow #6 Aluminum Lake, and the
1 mg also contains FD & C Blue #2 Aluminum Lake.
CONTRAINDICATIONS
id: 65baf8c0-f042-5050-e053-2a91aa0aa788
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3
Alprazolam tablets are contraindicated in patients with known sensitivity to this drug or other benzodiazepines. Alprazolam may be used in patients with open angle glaucoma who are receiving appropriate therapy, but is contraindicated in patients with acute narrow angle glaucoma.
Alprazolam is contraindicated with ketoconazole and itraconazole, since these medications significantly impair the oxidative metabolism mediated by cytochrome P450 3A (CYP3A) (see
WARNINGS
and
PRECAUTIONS: Drug Interactions
).
ADVERSE REACTIONS
id: 65baf8c0-f045-5050-e053-2a91aa0aa788
displayName: ADVERSE REACTIONS SECTION
FDA Article Code: 34084-4
Side effects to alprazolam tablets, if they occur, are generally observed at the beginning of therapy and usually disappear upon continued medication. In the usual patient, the most frequent side effects are likely to be an extension of the pharmacological activity of alprazolam, eg, drowsiness or light-headedness.
The data cited in the two tables below are estimates of untoward clinical event incidence among patients who participated under the following clinical conditions: relatively short duration (ie, four weeks) placebo-controlled clinical studies with dosages up to 4 mg/day of alprazolam (for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety) and short-term (up to ten weeks) placebo-controlled clinical studies with dosages up to 10 mg/day of alprazolam in patients with panic disorder, with or without agoraphobia.
These data cannot be used to predict precisely the incidence of untoward events in the course of usual medical practice where patient characteristics, and other factors often differ from those in clinical trials. These figures cannot be compared with those obtained from other clinical studies involving related drug products and placebo as each group of drug trials are conducted under a different set of conditions.
Comparison of the cited figures, however, can provide the prescriber with some basis for estimating the relative contributions of drug and non-drug factors to the untoward event incidence in the population studied. Even this use must be approached cautiously, as a drug may relieve a symptom in one patient but induce it in others. (For example, an anxiolytic drug may relieve dry mouth [a symptom of anxiety] in some subjects but induce it [an untoward event] in others.)
Additionally, for anxiety disorders the cited figures can provide the prescriber with an indication as to the frequency with which physician intervention (eg, increased surveillance, decreased dosage or discontinuation of drug therapy) may be necessary because of the untoward clinical event.
DOSAGE AND ADMINISTRATION
id: 65baf8c0-f048-5050-e053-2a91aa0aa788
displayName: DOSAGE & ADMINISTRATION SECTION
FDA Article Code: 34068-7
Dosage should be individualized for maximum beneficial effect. While the usual daily dosages given below will meet the needs of most patients, there will be some who require doses greater than 4 mg/day. In such cases, dosage should be increased cautiously to avoid adverse effects.
HOW SUPPLIED
id: 65baf8c0-f08f-5050-e053-2a91aa0aa788
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5
1 mg: Oval, blue tablets debossed GG 258 on one side and scored on the reverse side and supplied as:
NDC: 60760-0813-30 bottles of 30
ANIMAL STUDIES
id: 65baf8c0-f04a-5050-e053-2a91aa0aa788
displayName: ANIMAL PHARMACOLOGY & OR TOXICOLOGY SECTION
FDA Article Code: 34091-9
When rats were treated with alprazolam at 3, 10, and 30 mg/kg/day (15 to 150 times the maximum recommended human dose) orally for 2 years, a tendency for a dose related increase in the number of cataracts was observed in females and a tendency for a dose related increase in corneal vascularization was observed in males. These lesions did not appear until after 11 months of treatment.
Alprazolam
St Marys Medical Park Pharmacy
id: 65baf8c0-f04c-5050-e053-2a91aa0aa788
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4
